期刊
IMMUNOBIOLOGY
卷 227, 期 3, 页码 -出版社
ELSEVIER GMBH
DOI: 10.1016/j.imbio.2022.152212
关键词
Interleukin-2; Cyclophosphamide; CD8(+) T cell; NK cell; Regulatory T cell
类别
资金
- Higher-level New-type Talent Foundation of Guizhou Province [GZSYQCC (2016) 003]
- Non-profit central research Institute fund of Chinese academy of medical sciences [2019PT320003]
- Health Commission Science and Technology Foundation of Guizhou Province [gzwjkj 2020-1-032, gzwkj 2022-028]
Combining low-dose CTX with IL-2 in anti-tumor treatment can significantly inhibit tumor growth by inhibiting tumor cell proliferation and increasing apoptosis, as well as increasing the infiltration of CD8(+) T cells.
Interleukin-2 (IL-2) benefits some cancer patients by promoting the proliferation of cytotoxic effector T cells, but this process is limited by the expansion of regulatory T cells (Tregs). Low-dose cyclophosphamide (CTX) can inhibit the number and function of Tregs. We treated carcinoma-bearing mice with Vehicle, CTX, IL-2 and CTX + IL-2 to investigate the effects of low-dose CTX combined with IL-2 in antitumor treatment. In comparison to monotherapy, CTX + IL-2 significantly limited tumor growth, via tumor cell proliferation inhibition and increased apoptosis. The infiltration of CD8(+) T cells in tumor tissues was significantly increased in the CTX + IL-2 group. CTX + IL-2 safely increased CD8(+) T and natural killer cells in the spleen, lymph nodes and peripheral blood, and CTX attenuated the increase in Tregs induced by IL-2 in the spleen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据